Director, Cancer Immunotherapy
Martin Hosking, Director of Research & Development at the pioneering cell therapy company Fate Therapeutics in San Diego, has built a career over more than two decades in academia and biotech. His journey at Fate began in 2016 as a scientist, and he has since progressed through key leadership roles to become Director. Martin earned his Ph.D. in Biological Sciences from the University of California, Irvine, where he studied immune responses to coronaviruses and further refined this expertise during his time as a Postdoctoral Research Associate and Staff Scientist at The Scripps Research Institute in La Jolla, where he focused on the generation, regulation, and maintenance of immune responses.
At Fate Therapeutics, Martin plays a vital role in advancing off-the-shelf iPSC-derived immune cell therapies to clinical evaluation for patients with cancer. He guides major programs like FT825/ONO 8250 and FT836, and he has recently secured CIRM funding for the pre- and non-clinical development of FT836. Martin’s work has been featured in high-impact journals, conference presentations, and several patent filings focused on genetically engineered immune cells as novel therapeutic options for patients.